Long-term treatment of gastro-oesophageal reflux disease patients with frequent symptomatic relapses using rabeprazole: On-demand treatment compared with continuous treatment

Alimentary Pharmacology and Therapeutics

Volumn 21, Issue 7, 2005, Pages 805-812

  Bour, B ^a   Staub, J L ^b   Chousterman, M ^c   Labayle, D ^d   Nalet, B ^e   Nouel, O ^f   Pariente, A ^g   Tocque, E ^a,h   Bonnot Marlier, S ^a,h  

^a CENTRE HOSPITALIER DU MANS   (France)

^b Centre Hospitalier Georges Renon   (France)

^c CENTRE HOSPITALIER INTERCOMMUNAL DE CRÉTEIL   (France)

^d Hopital Louise Michel   (France)

^e Montelimar Hospital   (France)

^f Yves Le Foll Hospital   (France)

^g Laboratoires   (France)

^h Assoc Natl Hepatogastroent H G ^*

Author keywords

[No Author keywords available]

Indexed keywords

ESOMEPRAZOLE; OMEPRAZOLE; PLACEBO; RABEPRAZOLE;

ABDOMINAL PAIN; ADULT; ARTICLE; BRONCHITIS; CLINICAL TRIAL; CONTINUOUS TREATMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTITIS; DIARRHEA; DRUG THERAPY; FEMALE; GASTROENTERITIS; GASTROESOPHAGEAL REFLUX; HEADACHE; HUMAN; LONG TERM CARE; LOW BACK PAIN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; ON DEMAND TREATMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RELAPSE; SIDE EFFECT; STOMACH ACID SECRETION; SYMPTOMATOLOGY; TREATMENT OUTCOME; URINARY FREQUENCY; VERTIGO; VOMITING;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; AGED; ANTI-ULCER AGENTS; BENZIMIDAZOLES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; OMEPRAZOLE; PATIENT COMPLIANCE; RECURRENCE; TREATMENT OUTCOME;

EID: 16444386234     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2005.02413.x     Document Type: Article

References (22)

1. Locke GR, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ. Prevalence and clinical spectrum of gastro-esophageal reflux: a population-based study in Olmsted county, Minnesota. Gastroenterology 1997; 112: 1448-56.
2. Vallot T, Bruley des Varannes S, Grimaud JC, et al. Epidémiologie du reflux gastro-oesophagien en médecine générale: facteurs prédictifs de la consommation de soins sur un an. Gastroenterol Clin Biol 1999; 23: 1139-44.
3. Fass R, Ofman JJ. Gastroesophageal disease: should we adopt a new conceptual framework? Am J Gastroenterol 2002; 97: 1901-9.
4. Gastroesophageal reflux in adults: diagnosis and treatment. Conclusions of Consensus Conference: long text. Organized by the French National Society of Gastroenterology and Belgian Royal Society of Gastroenterology/Flemish Society of Gastroenterology. French Society of Digestive Surgery. French Society of Digestive Endoscopy. French Society of Pharmacology [In French]. Gastroenterol Clin Biol 1999; 23: 56-65.
5. Havelund T, Lind T, Wiklund I, et al. Quality of life in patients with heartburn with oesophagitis: effects of omeprazole. Am J Gastroenterol 1999; 94: 1782-9.
6. Tytgat GNJ. Review article: management of mild and severe gastro-esophageal reflux disease. Aliment Pharmacol Ther 2003; 17(Suppl. 2): 52-6.
7. Hungin APS, Rubin G, O'Flanagan H. Factors influencing compliance in long-term proton pump inhibitor therapy in general practice. Br J Gen Pract 1999; 49: 463-4.
8. Lind T, Havelund T, Glise H, et al. On-demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis - a placebo-controlled randomized trial. Aliment Pharmacol Ther 1999; 13: 907-14.
9. Talley NJ, Lauritsen K, Tunturi-Hihnala H, et al. Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: a controlled trial of 'on-demand' therapy for 6 months. Aliment Pharmacol Ther 2001; 15: 347-54.
10. Talley NJ, Venables TL, Green J, et al. Esomeprazole 40 mg and 20 mg is efficacious in the long-term management of patients with endoscopy-negative gastro-oesophageal reflux disease: a placebo-controlled trial of on-demand therapy for 6 months. Eur J Gastroenterol Hepatol 2002; 14: 857-63.
11. Bytzer P, Blum A, De Herdt D, Dubois D: The trial investigators. Six-month trial of on-demand rabeprazole 10 nig maintains symptom relief in patients with non-erosive reflux disease. Aliment Pharmacol Ther 2004; 20: 181-8.
12. Amouretti M, Galmiche JP. Questionnaire de qualité de vie dans le reflux gastro-oesophagien. Gastroenterol Clin Biol 1999; 23: 32-9.
13. Ofman JJ. The economic and quality-of-life impact of symptomatic gastroesophageal reflux disease. Am J Gastroenterol 2003; 98(Suppl.): 8-14.
14. Engels LGJB, Klinkenberg-Knol EC, Dekkers CPM, et al. Esomeprazole continuous versus on-demand maintenance therapy in 1052 gastro-oesophageal reflux disease patients: similar satisfaction but superior quality of life for once daily treatment [Abstract], Gut 2003; 52(Suppl. VI): A130.
15. McDougall NI, Johnston BT, Kee F, et al. Natural history of reflux oesophagitis: a 10-year follow-up of its effect on patient symptomatology and quality of life. Gut 1996; 38: 481-6.
16. Johnsson F, Moun B, Vilien M, et al. On-demand treatment in patients with oesophagitis and reflux symptoms: comparison of lansoprazole and orneprazole. Scand J Gastroenterol 2002; 14: 857-63.
17. Pantoflickova D, Corta G, Ravie M, et al. Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors. Aliment Pharmacol Ther 2003; 17: 1507-14.
18. Scott LJ, Esomeprazole: a review of its use in the management of acid-related disorders. Drugs 2002; 62: 1503-38.
19. Modlin IM, Sachs G. Acid Related Diseases - Biology and Treatment. Munich: Schnetztor-Verlag-GmbH Konstanz. 1998.
20. Bruley des Varannes S, Gharib H, Bicheler V. et al. Effect of low-dose rabeprazole and orneprazole on gastric acidity: results of a double blind, randomised, placebo-controlled, three-way crossover study in healthy subjects. Aliment Pharmacol Ther 2004; 20: 899-907.
21. Williams MP, Sercombe J, Hamilton MI, et al. A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus orneprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects. Aliment Pharmacol Ther 1998; 12: 1079-89.
22. Quigley EM. Noneroslve reflux disease: part of the spectrum of gastro-oesophageal reflux disease, a component of functional dyspepsia, or both? [Review], Eur J Gastroenterol Hepatol 2001; 13(Suppl. 1): S13-8.